论文部分内容阅读
在确定宫颈癌治疗计划时,了解癌灶的范围是最重要的因素.治疗前,双合诊检查估计癌灶范围的方法是必要的,但双合诊估价的临床分期和术时所见的病变范围常有误差。本文作者认为测定血中TA—4, 方法简单、容易,在治疗前测定TA—4对于予测宫颈癌的范围有一定价值.作者对诊断为宫颈鳞状细胞癌,开始用手术治疗的96例患者,术前2—5天取血标本,用放射免疫分析法测血中TA—4的水平.所有患者术前均根据国际妇
In determining the treatment plan for cervical cancer, understanding the extent of the cancer is the most important factor. Before treatment, the method of double-checking the range of estimated tumors is necessary, but the clinical stage and the time of the surgery are the same for the double-combined diagnosis. The range of lesions is often error. The author believes that the determination of TA-4 in blood is simple and easy. The determination of TA-4 before treatment has a certain value for the scope of preclinical cervical cancer. The authors diagnosed squamous cell carcinoma of the cervix and started surgery with 96 cases. Patients, blood samples were taken 2 to 5 days before surgery, and the level of TA-4 in blood was measured by radioimmunoassay. All patients were preoperatively based on international women.